Pulak Sharma and Dr. Priyanka Sharma of Kazmira-LLC gave the audience an inside look at what it takes to operate the world’s largest CBD manufacturing facility. This presentation was given at the Hemp Summit inside NoCo 2018 in Loveland, Colorado.
Video credit: Hemp Summit and Green Flower
Note: FDA has not evaluated these products for safety and efficacy.
A study published in peer review Neuropsychopharmacology showed that cannabidiol, more commonly known as CBD, can potentially help decrease relapse behavior in cases of drug or alcohol addiction.
Researchers at the Scripps Research Institute in La Jolla, California, conducted the pre-clinical study. Using rats that had a history of self-administered addiction to alcohol or cocaine, researchers administered transdermal CBD to the test subjects every 24 hours, for seven days.
Following the week-long CBD treatment, rats were tested for addictive Broad Spectrum CBD behavior response. The study showed a decreased level of “context-induced or stress-induced drug seeking How to make 10 behaviors.” After transdermal CBD Tiger Balm Alternative was ceased, the rats still Broad Spectrum CBD showed benefits for up to Salonpas Alternative five months, though CBD levels were detectable for only three days after treatment. It also was noted the rats showed no effects that interfered with normal motivation or resulted in sedative effects. Cannabidiol has no psychoactive effect.
Study lead author Gustavo Gonzales Cuevas and research team said that study results would contribute to the debate around the disputed medical benefits of cannabis. Federal schedule one status for cannabis means it is defined as having “no medical benefits,” and prohibits clinical research of cannabis in the United States.